Pricing Log in Create free account
Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue
+36.3%
EPS
+36.0%
Free cash flow
+3.85%
Total debt
−26.6%

Quarter to September 2026, against a year earlier

909.40 6.50 +0.72%
Market cap
$93.4B
P/E
19.2×
Fwd P/E
19.2×
Dividend yield
0.41%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. (REGN) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a EV/EBITDA of 16.0×. Over the past ten years it has ranged from 5.9× (June 2022) to 56.4× (June 2015); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 18.5× 15.00%
FY2024 16.1× (19.97%)
FY2023 20.1× 38.87%
FY2022 14.5× 107.32%
FY2021 7.0× (49.33%)
FY2020 13.8× (13.29%)
FY2019 15.9× 11.73%
FY2018 14.2× (20.72%)
FY2017 18.0× (34.01%)
FY2016 27.2× (34.66%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 13.3× (2.73%)
Jun 2026 13.6× (24.31%)
Mar 2026 18.0× (2.76%)
Dec 2025 18.5× 44.48%
43 more quarters

Against its own ten years

Low 5.9× High 56.4×
Ten-year median 16.9×
Current reading's percentile 44

EV/EBITDA against peers

Company EV/EBITDA
ROIV Roivant Sciences Ltd. compare n/m
MRNA Moderna, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
REGN Regeneron Pharmaceuticals, Inc. 16.0×
RPRX Royalty Pharma PLC compare 24.7×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 28.6×
VRTX Vertex Pharmaceuticals Incorporated compare 29.7×
ARGX argenex SE compare 30.4×
GMAB Genmab A/S Sponsored ADR compare 31.0×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on REGN